Deep 6 AI, a Pasadena, Calif.-based provider of clinical trials acceleration software, raised $17M in Series A funding.
The round was led by Point72 Ventures, with participation from GSR Ventures and strategic partners. As part of this investment, Point72 Ventures partner Daniel Gwak will join the Deep 6 AI Board of Directors.
The company intends to use the funds to expand its business reach among healthcare providers, pharma companies, and contract research organizations and enhance its suite of AI-native software products.
Founded in 2015 and led by CEO Wout Brusselaers, Deep 6 AI provides a suite of AI-driven tools designed to accelerate and optimize clinical trials design, recruitment, and management. The company’s solution uses AI to parse clinical trial qualification criteria and match against repositories of structured and unstructured patient health data at participating trial sites. This allows teams running clinical trials to identify and review qualified patients in a matter of minutes. It also allows trial sponsors and healthcare providers to know in advance where to find qualified patients before they invest in activating trial sites and recruiting patients.
Customers include Cedars Sinai Medical Center and Texas Medical Center, among several other large health systems across the U.S., in addition to a number of large life sciences companies, medical device companies and contract research organizations.